Cart
sales@molnova.com
Duvelisib
CAS No. 1201438-56-3
Duvelisib( IPI-145 | INK-1197 )
Catalog No. M10723 CAS No. 1201438-56-3
A potent, selective PI3Kδ/γ inhibitor with Ki of 23 pM/243 pM, IC50 of 1 nM/50 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 38 | In Stock |
|
| 5MG | 58 | In Stock |
|
| 10MG | 81 | In Stock |
|
| 50MG | 147 | In Stock |
|
| 100MG | 238 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDuvelisib
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, selective PI3Kδ/γ inhibitor with Ki of 23 pM/243 pM, IC50 of 1 nM/50 nM.
-
DescriptionA potent, selective PI3Kδ/γ inhibitor with Ki of 23 pM/243 pM, IC50 of 1 nM/50 nM; displays high selectivity for PI3K δ/γ than other protein kinases; exerts profound effects on adaptive and innate immunity by inhibiting B and T cell proliferation, blocking neutrophil migration, and inhibiting basophil activation; exhibits potent activity in collagen-induced arthritis, ovalbumin-induced asthma, and systemic lupus erythematosus rodent models.Blood Cancer Phase 3 Clinical.
-
In VitroPI3Kδ and PI3Kγ inhibition with Duvelisib (IPI-145) has anti-proliferative activity in primary AML cells by inhibiting the activity of AKT and MAPK. Pre-treatment of AML cells with Duvelisib inhibits both adhesion and migration of AML blasts to bone marrow stromal cells.
-
In Vivo——
-
SynonymsIPI-145 | INK-1197
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptorPI3Kα|PI3Kβ|PI3Kγ|PI3Kδ
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number1201438-56-3
-
Formula Weight416.863
-
Molecular FormulaC22H17ClN6O
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 41 mg/mL
-
SMILESO=C1N(C2=CC=CC=C2)C([C@@H](NC3=C4N=CNC4=NC=N3)C)=CC5=C1C(Cl)=CC=C5
-
Chemical Name1(2H)-Isoquinolinone, 8-chloro-2-phenyl-3-[(1S)-1-(9H-purin-6-ylamino)ethyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Winkler DG, et al. Chem Biol. 2013 Nov 21;20(11):1364-74.
2. Boyle DL, et al. J Pharmacol Exp Ther. 2014 Feb;348(2):271-80.
3. Dong S, et al. Blood. 2014 Dec 4;124(24):3583-6.
molnova catalog
related products
-
Copanlisib dihydroch...
Copanlisib dihydrochloride is an ATP-competitive pan-class I PI3K inhibitor (IC50s: 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ).
-
STX-478
STX-478 is an orally active and selective PI3Kα inhibitor that penetrates the blood-brain barrier and has anticancer activity to inhibit tumor growth.STX-478 is indicated for the study of breast cancer and other cancers.
-
Parsaclisib HCl
Parsaclisib HCl is a selectve PI3Kδ inhibitor with antitumor activity. Parsaclisib demonstrates potent activity with IC50 values ranging from 0.2 to 2 nM.
